28
Interventional Cardiology
Baylor Scott & White Heart and Vascular Hospital — Dallas | Interventional Cardiology
YEAR IN REVIEW
FY24
10,853
Total cardiac cath lab procedures
8,280
Cath lab cases
4,687
Diagnostic cardiac procedures
1,817
Total percutaneous coronary interventions
For cardiovascular disease diagnosis and treatment , innovation leads the way at Baylor Scott & White Heart and Vascular Hospital – Dallas ’ Interventional Cardiology Department . The Department has a total of 11 cath labs , well-equipped for both heart and vascular care . Four of the labs are heart and vascular capable , five are electrophysiology capable , one is used for endovascular cases , and two are hybrid rooms . The labs offer advanced image quality and radiation lowering equipment for patient and staff safety .
There are few specialized heart and vascular hospitals and cath lab departments across the United States that offer such a broad range of interventional cardiology treatment options with treatment options regularly added . In many instances , first-to-commercial market , post-FDA approval use of devices or procedures using new tools , occur on the Dallas campus as a result of involvement in clinical trials .
Fiscal year 2024 “ firsts ”
Robert Stoler , MD , FACC , FSCAI - Medical Director , Cardiology and Catheterization Labs
Renal denervation approved : Dallas campus 1st in Texas
Robert Stoler , MD , FACC , FSCAI , medical director for the catheterization labs in Dallas , performed the first commercial case in Texas and second in the US using Medtronic Symplicity Spyral™ renal denervation ( RDN ) system . Also known as the Symplicity Spyral blood pressure procedure , the system received approval from the FDA in November 2023 . The Dallas campus was one of the sites involved in the studies for the past decade to bring this treatment option to patients with resistant hypertension . The studies included Spyral On Med , which completed enrollment in March 2022 , Spyral Off Med and Spyral Dystal .
Dr . Stoler was also the first in Texas to use the Recor Medical ® Paradise ® ultrasound renal denervation system in a commercial case .
Patients who undergo renal denervation will be followed closely through the Hypertension Center ’ s team .
For more information about the Hypertension Center in Dallas , please call 214.820.7148 .
First drug-coated PTCA balloon catheter case
The first in Texas commercial paclitaxel coated PTCA balloon catheter was used by Dr . Stoler in May 2023 . This is a treatment option for patients with in-stent restenosis and ultimately small vessels .
The AGENT™ drug-coated balloon is a femoral device that transfers a therapeutic dose of paclitaxel to the artery wall to help prevent a reoccurrence of the narrowing of the artery . For more than four years , Dr . Stoler was the principal investigator and member of the national steering committee for AGENT-IDE randomized clinical trial on the Dallas campus . The site was one of the top enrolling sites in the US .
Dr . Stoler was one of the lead authors for the article , Paclitaxel-coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis . The article provides an overview of AGENT IDE , a multicenter randomized trial of 600 patients designed to evaluate the paclitaxel-coated balloon as a treatment strategy . Journal American Medical Association . 2024 March 15 ; 215:56-57